Mahana Therapeutics, a San Francisco, CA-based developer of prescription digital therapeutics designed to empower patients with chronic health conditions, raised $61m in Series B financing.
The round was led by JAZZ Venture Partners and Gurnet Point Capital with participation from new and existing investors Main Street Advisors, KKCG and Lux Capital. Sophie Kornowski of Gurnet Point and Meghan Reynolds of JAZZ have joined the Mahana Therapeutics Board of Directors.
The company will use the funds to launch the FDA-cleared prescription digital therapeutic Mahana™ IBS and accelerate development of several digital therapeutics for chronic health conditions.
Led by Steven Basta, chief executive officer, Mahana Therapeutics is a developer of prescription digital therapeutics that are designed to empower patients with chronic conditions. The company’s first product, Mahana IBS, is a digital therapeutic that has demonstrated effectiveness in a 558-patient clinical trial in individuals with irritable bowel syndrome and has received FDA clearance for that treatment.
The digital therapeutic device is indicated as a three-month treatment providing cognitive behavioral therapy (CBT) to adults with IBS through a downloadable app available for iOS and Android phones and tablets.
FinSMEs
11/08/2021